(Q36666936)

15 August 2017

Value of a complete or partial remission in severe lupus nephritis (English)

1 reference

Collaborative Study Group

15 August 2017

6

object named as

Collaborative Study Group

1 reference

15 August 2017

Yiann E Chen

1

1 reference

15 August 2017

Stephen M Korbet

2

1 reference

15 August 2017

Robert S Katz

3

1 reference

15 August 2017

Melvin M Schwartz

4

1 reference

15 August 2017

Edmund J Lewis

5

1 reference

15 August 2017

14 November 2007

1 reference

Clinical Journal of the American Society of Nephrology

15 August 2017

1 reference

15 August 2017

3

1 reference

15 August 2017

1

1 reference

15 August 2017

46-53

1 reference

Clinical presentation and monitoring of lupus nephritis

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

The classification of glomerulonephritis in systemic lupus erythematosus revisited

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

The 1982 revised criteria for the classification of systemic lupus erythematosus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Prognostic factors in lupus nephritis. Contribution of renal histologic data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Identification of antinative DNA antibodies in cryoglobulinemic states

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Sustained remission of lupus nephritis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390978

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

20 September 2018

1 reference

12 December 2020

Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

12 December 2020

Response to treatment as a predictor of longterm outcome in patients with lupus nephritis

1 reference

12 December 2020

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

12 December 2020

Outcome criteria for lupus nephritis trials: a critical overview

1 reference

12 December 2020

Mycophenolate mofetil for remission induction in severe lupus nephritis

1 reference

12 December 2020

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide

1 reference

12 December 2020

Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

1 reference

12 December 2020

Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis

1 reference

12 December 2020

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

12 December 2020

Idiopathic membranous nephropathy: definition and relevance of a partial remission

1 reference

12 December 2020

Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization

1 reference

12 December 2020

Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis

1 reference

12 December 2020

A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease

1 reference

12 December 2020

Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.03280807

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18003764

1 reference